<DOC>
	<DOCNO>NCT02795897</DOCNO>
	<brief_summary>The purpose study look abnormal gene gene expression profile help determine person develop amyotrophic lateral sclerosis ( ALS ) relate motor neuron disease ( MND ) symptoms present progress particular pattern .</brief_summary>
	<brief_title>Genomic Translation ALS Care</brief_title>
	<detailed_description>In patient , ALS/MND cause progressive death motor neuron . However , every patient affect differently . Some develop symptoms 80 's others get sick adolescence . Swallowing/speech affect first patient , weakness hand foot onset . Some individual show rapid progression , even others live decade . Finally , patient loss mainly motor neuron brain ( primary lateral sclerosis ) , others lose mainly low motor neuron spinal cord brain stem ( progressive muscular atrophy ) . Research uncovered genetic factor contribute variability ALS/MND . For example , mutation superoxide dismutase 1 ( SOD1 ) gene make onset leg likely decrease chance develop dementia . Conversely , mutate C9ORF72 gene make dementia much likely . Uncovering additional factor cause ALS variability important research priority likely provide clue well diagnose treat disease . This study call `` Genomic Translation ALS Care '' ( GTAC ) . The investigator analyze genome gene expression pattern people ALS/MND carry research data , find insight investigator hope translate good care ALS/MND patient .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Study participant meet follow criterion eligible enrollment GTAC : 1 . Men woman race ethnicity age 18 old 2 . Diagnosis familial sporadic ALS ( definite , probable , possible accord El Escorial Criteria , Appendix 1 ) , primary lateral sclerosis progressive bulbar/muscular atrophy form motor neuron disease . Allcomers ALS/MND enrol without regard familial v sporadic gene mutation status ( i.e . participant know gene mutation still enrol ) , phenotype . 3 . Capable provide informed consent follow study procedure ( case subject lack ability provide inform consent , informed consent seek subject 's surrogate representative ) . 4 . Willing return clinic site ( another participate center ) followup care . Study participant meet follow criterion screen evaluation exclude enrol GTAC : 1 . Invasive ventilation ( i.e . tracheostomy ) place . 2 . Noninvasive ventilation dependent ( define &gt; 22 hour per day ) 3 . Pregnancy . 4 . Known Human Immunodeficiency Virus ( HIV ) , chronic Hepatitis B , Hepatitis C ( cell freeze future cell line generation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>genetics</keyword>
	<keyword>genomics</keyword>
	<keyword>amyotrophic lateral sclerosis ( ALS )</keyword>
	<keyword>primary lateral sclerosis ( PLS )</keyword>
	<keyword>progressive muscular atrophy ( PMA )</keyword>
	<keyword>motor neuron disease</keyword>
</DOC>